The in vivo CAR-T field crossed a critical threshold in late 2025, with first-in-human data confirming that both LNP and lentiviral platforms can successfully direct endogenous T cells to deplete B cells in living patients. Currently, China hosts a disproportionate share of the world’s clinical-stage in vivo programs.

This proprietary report by Selesta explores the structural drivers behind China’s clinical lead, the $7.5B+ wave of global deal validation, and the competitive dynamics of the 18 active Chinese programs. Crucially, it outlines the dense 2026 clinical readout calendar—a catalyst window that will serve as either a massive de-risking event or a source of sector-wide binary risk.

Key Highlights:

• Accelerated Clinical Timelines: The IIT pathway allows Chinese biotechs to generate human proof-of-concept data faster than global peers, creating a distinct competitive advantage.
• Breakthrough First-in-Human Data: Published results confirm the biological activity of in vivo CAR-T in autoimmune and oncology indications, supported by promising safety profiles.
• Global Validation Through Mega-Deals: Over $7.5 billion in recent transactions reflect growing global confidence in both lentiviral and LNP platforms.
• Upcoming 2026 Catalysts: A dense clinical readout calendar featuring key programs from MagicRNA, CSPC, and others, which will either de-risk the sector or introduce new challenges.
• Reimbursement Potential: The manufacturing cost advantages of in vivo CAR-T provide a viable pathway for broader commercial adoption within China’s CHIIDL and NRDL frameworks.

This report offers a comprehensive analysis of China’s pipeline, the evolving competitive landscape, and its strategic implications for global biopharma players.
Read the full report for detailed insights and proprietary data.

Prepared by the Selesta Research Team | research@selesta.ai
Selesta is a healthcare and life science advisory firm dedicated to serving Asia’s emerging entrepreneurs and businesses.

DISCLAIMER: This document is prepared by Selesta Partners Limited for information purposes only. Neither Selesta nor the Directors of the company accept any responsibility for the accuracy or completeness of information provided by third parties. It should not be copied or distributed without written consent. The views expressed are subject to change. This material does not constitute investment advice or an offer to sell any securities.